Explore more publications!

Guinea Bissau Health Bulletin: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guinea Bissau Health Bulletin.

Press releases published on October 28, 2025

Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
BioNTech veranstaltet am 11. November 2025 „Innovation Series Day“ zu Forschung & Entwicklung
BioNTech to Host Innovation Series R&D Day on November 11, 2025
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Context Therapeutics to Participate in Upcoming Investor Conferences
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
KFSHRC, 사우디 최초의 유전자·세포치료제 제조 시설 구축 발표
KFSHRC 将启用沙特阿拉伯首个基因和细胞疗法产品生产基地
KFSHRC、サウジアラビア初の遺伝子・細胞治療製造施設を開設
KFSHRC Melancarkan Fasiliti Pertama untuk Pengeluaran Terapi Gen dan Sel di Arab Saudi
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions